BSE Live
Mar 20, 16:01Prev. Close
113.70
Open Price
113.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 20, 15:59Prev. Close
114.36
Open Price
116.08
Bid Price (Qty.)
118.22 (2225)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Kopran (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 48.29 | 48.21 | 48.21 | 48.21 | 43.25 | |
| Total Share Capital | 48.29 | 48.21 | 48.21 | 48.21 | 43.25 | |
| Reserves and Surplus | 383.15 | 368.66 | 347.38 | 330.51 | 203.60 | |
| Total Reserves and Surplus | 383.15 | 368.66 | 347.38 | 330.51 | 203.60 | |
| Total Shareholders Funds | 431.44 | 416.87 | 395.59 | 378.72 | 246.85 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 3.56 | 2.23 | 2.30 | 2.08 | 2.36 | |
| Deferred Tax Liabilities [Net] | 2.82 | 2.67 | 2.85 | 3.03 | 2.31 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 5.34 | 4.57 | 4.33 | 4.03 | 3.86 | |
| Total Non-Current Liabilities | 11.72 | 9.47 | 9.48 | 9.14 | 8.53 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 41.75 | 20.49 | 25.58 | 34.74 | 13.26 | |
| Trade Payables | 46.49 | 51.78 | 62.36 | 29.79 | 39.96 | |
| Other Current Liabilities | 14.14 | 11.40 | 12.20 | 10.95 | 14.72 | |
| Short Term Provisions | 0.94 | 0.88 | 0.74 | 0.77 | 0.64 | |
| Total Current Liabilities | 103.33 | 84.54 | 100.88 | 76.25 | 68.57 | |
| Total Capital And Liabilities | 546.48 | 510.88 | 505.95 | 464.12 | 323.95 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 61.20 | 51.13 | 45.82 | 44.05 | 44.60 | |
| Intangible Assets | 0.25 | 0.89 | 1.53 | 2.18 | 2.84 | |
| Capital Work-In-Progress | 2.10 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 68.88 | 56.72 | 50.88 | 49.32 | 50.26 | |
| Non-Current Investments | 263.07 | 261.27 | 260.07 | 259.43 | 158.79 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 2.92 | 2.91 | |
| Other Non-Current Assets | 5.48 | 5.18 | 4.59 | 1.14 | 0.87 | |
| Total Non-Current Assets | 337.44 | 323.17 | 315.54 | 312.81 | 212.84 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 55.75 | 49.49 | 47.60 | 41.51 | 27.50 | |
| Trade Receivables | 91.92 | 87.80 | 83.81 | 59.13 | 49.46 | |
| Cash And Cash Equivalents | 21.02 | 7.42 | 2.59 | 2.55 | 3.22 | |
| Short Term Loans And Advances | 1.70 | 0.91 | 0.63 | 0.49 | 0.36 | |
| OtherCurrentAssets | 38.67 | 42.08 | 55.78 | 47.63 | 30.56 | |
| Total Current Assets | 209.05 | 187.70 | 190.41 | 151.31 | 111.12 | |
| Total Assets | 546.48 | 510.88 | 505.95 | 464.12 | 323.95 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 64.56 | 57.76 | 48.11 | 45.45 | 54.96 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 33.64 | 65.85 | 40.32 | 14.40 | 32.13 | |
| Stores, Spares And Loose Tools | 8.81 | 0.00 | 15.45 | 0.00 | 0.00 | |
| Trade/Other Goods | 8.81 | 0.00 | 15.45 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 1.79 | 0.00 | 0.21 | 0.16 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 5.00 | 7.58 | 6.66 | 6.22 | 5.08 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | 257.88 | 272.73 | 246.42 | 194.93 | 199.04 | |
| Other Earnings | -- | -- | -- | -- | -- | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 9.80 | 9.80 | 9.80 | 9.80 | 9.80 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 263.06 | 261.26 | 260.06 | 259.41 | 158.79 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
23.01.2026
Kopran Consolidated December 2025 Net Sales at Rs 194.28 crore, up 16.87% Y-o-Y
23.01.2026
Kopran Standalone December 2025 Net Sales at Rs 93.88 crore, up 30.51% Y-o-Y
19.11.2025
Kopran Consolidated September 2025 Net Sales at Rs 117.91 crore, down 22.2% Y-o-Y
13.11.2025
Kopran Standalone September 2025 Net Sales at Rs 42.39 crore, down 42.35% Y-o-Y
23.01.2026
Kopran Consolidated December 2025 Net Sales at Rs 194.28 crore, up 16.87% Y-o-Y
23.01.2026
Kopran Standalone December 2025 Net Sales at Rs 93.88 crore, up 30.51% Y-o-Y
19.11.2025
Kopran Consolidated September 2025 Net Sales at Rs 117.91 crore, down 22.2% Y-o-Y
13.11.2025
Kopran Standalone September 2025 Net Sales at Rs 42.39 crore, down 42.35% Y-o-Y
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
20.03.2026
Semaglutide’s patent expires today. What does it mean for patients, pharma players and Novo Nordisk?
20.03.2026
20.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth